Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis-Reference-Cited by-同舟云学术

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis

Published:2020-04 Issue:4 Volume:13 Page:743-751
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Paul Stéphane¹^ORCID,Marotte Hubert²,Kavanaugh Arthur³,Goupille Philippe⁴,Kvien Tore K.⁵,Longueville Marc⁶,Mulleman Denis⁴,Sandborn William J.⁷,Vande Casteele Niels⁷

Affiliation:

1. Department of Immunology CIC1408 GIMAP EA3064 Université Jean Monnet Saint Étienne France

2. Department of Rheumatology SAINBOISE AINBIOSE INSERM 1059 University of Lyon Saint‐Étienne France

3. Division of Rheumatology, Allergy & Immunology University of California San Diego School of Medicine La Jolla California USA

4. Department of Rheumatology University Hospital of ToursEA 7501 Tours France

5. Department of Rheumatology Diakonhjemmet Hospital Oslo Norway

6. UCB Pharma Brussels Belgium

7. Department of Medicine University of California San Diego La Jolla California USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12760

Reference68 articles.

1. Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

2. An Examination of the Mechanisms Involved in Secondary Clinical Failure to Adalimumab or Etanercept in Inflammatory Arthropathies

3. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

4. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation

5. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimized Treatment of Interleukin (IL-1)-Mediated Autoinflammatory Diseases: Impact of Disease Activity-Based Treatment Adjustments;Journal of Clinical Medicine;2024-04-17

2. Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis;Modern Rheumatology;2023-10-13

3. Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials;Arthritis Research & Therapy;2023-04-13

4. Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor;Modern Rheumatology;2023-04-01

5. Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider;RMD Open;2022-06